H.C. Wainwright raised the firm’s price target on IO Biotech (IOBT) to $14 from $12 and keeps a Buy rating on the shares following the Q1 report. The firm cites lower than expected operating expenses for the target increase. The analyst says IO’s Phase 3 advanced melanoma data is on track for Q3.
Confident Investing Starts Here:
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IOBT:
Disclaimer & DisclosureReport an Issue